FDA approves first OTC glucose monitor for children

• Stelo uses a wearable sensor and smartphone app to display glucose readings and trends every 15 minutes, with each sensor lasting up to 15 days (potentially shorter in children)
• The device is intended to help children and caregivers understand how meals, exercise, and lifestyle affect glucose levels, but requires adult supervision
• The monitor is not designed for patients with problematic low blood sugar, as it does not alert users to this potentially dangerous condition

FDA Approves First OTC Glucose Monitor for Children

Key Development:

The U.S. Food and Drug Administration (FDA) announced on June 12 that it has expanded approval of Dexcom's Stelo Glucose Biosensor System to include children with diabetes, marking the first over-the-counter (OTC) continuous glucose monitor cleared for pediatric use.

Regulatory Details:

• The device is now approved for patients aged 2 years and older who do not use insulin
• Initial FDA clearance for adults aged 18 and older was granted in March 2024
• The expansion represents a significant milestone in accessible diabetes management technology

Product Specifications:

• Stelo utilizes a wearable sensor paired with a smartphone app to continuously track glucose levels
• Provides glucose readings and trend data every 15 minutes
• Each sensor lasts up to 15 days, though duration may be shorter in pediatric patients

Usage Guidelines:

• Designed to help children and caregivers understand how diet, exercise, and lifestyle impact glucose levels
• Requires adult supervision for pediatric use
• Users should consult healthcare providers before making medication adjustments based on readings
• Not suitable for individuals with problematic hypoglycemia, as the device lacks alerts for dangerously low blood sugar levels

Market Implications:

This approval significantly expands Dexcom's addressable market in the diabetes management sector, potentially capturing a substantial portion of the pediatric diabetes population. The OTC designation eliminates prescription requirements, improving accessibility and likely driving adoption. This regulatory win strengthens Dexcom's competitive position in the growing continuous glucose monitoring market, which serves millions of diabetes patients seeking non-invasive monitoring solutions.